Estimation of rivaroxaban plasma concentrations in the perioperative setting in patients with or without Heparin Bridging

Clinical and Applied Thrombosis/Hemostasis

Volumn 24, Issue 1, 2018, Pages 129-138

  Lessire, Sarah ^a,b   Douxfils, Jonathan ^b   Pochet, Lionel ^b   Dincq, Anne Sophie ^a   Larock, Anne Sophie ^a   Gourdin, Maximilien ^a   Dogné, Jean Michel ^b   Chatelain, Bernard ^a   Mullier, François ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b University of Namur   (Belgium)

Author keywords

Anticoagulants; Drug monitoring; Heparin; Low molecular weight; Perioperative period; Rivaroxaban

Indexed keywords

BLOOD CLOTTING FACTOR 10A; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

ARTICLE; ATRIAL FIBRILLATION; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG MONITORING; ELECTROSPRAY MASS SPECTROMETRY; HEMOSTASIS; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SECONDARY PREVENTION; THROMBOCYTE POOR PLASMA; VENOUS THROMBOEMBOLISM; ADULT; BLOOD; CLINICAL TRIAL; FEMALE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; THROMBOEMBOLISM;

ADULT; CHROMATOGRAPHY, LIQUID; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MASS SPECTROMETRY; PERIOPERATIVE CARE; RIVAROXABAN; THROMBOEMBOLISM;

EID: 85042042634     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029616675968     Document Type: Article

References (33)

1. Douxfils J, Mani H, Minet V, et al. Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations. BioMed Res Int. 2015;2015:345138.
2. Sherwood MW, Douketis JD, Patel MR, et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014;129(18): 1850-1859.
3. Beyer-Westendorf J, Gelbricht V, Forster K, et al. Periinterventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014;35(28):1888-1896.
4. Godier A, Martin AC, Leblanc I, et al. Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations. Thromb Res. 2015; 136(4):763-768.
5. Kepplinger J, Prakapenia A, Barlinn K, et al. Standardized use of novel oral anticoagulants plasma level thresholds in a new thrombolysis decision making protocol. J Thromb Thrombolysis. 2016; 41(2):293-300.
6. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1128-1139.
7. Samama MM, Contant G, Spiro TE, et al; Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107(2):379-387.
8. Douxfils J, Mullier F, Loosen C, Chatelain C, Chatelain B, Dogne JM. Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res. 2012;130(6): 956-966.
9. Harenberg J, Kramer R, Giese C, Marx S, Weiss C, Wehling M. Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis. 2011;32(3):267-271.
10. Asmis LM, Alberio L, Angelillo-Scherrer A, et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res. 2012;129(4): 492-498.
11. Douxfils J, Lessire S, Dincq AS, et al. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays. Thromb Haemost. 2015;113(4):862-869.
12. Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost. 2012;108(1):191-198.
13. Konigsbrugge O, Quehenberger P, Belik S, et al. Anti-coagulation assessment with prothrombin time and anti-Xa assays in realworld patients on treatment with rivaroxaban. Ann Hematol. 2015;94(9):1463-1471.
14. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban on coagulation assays. Int J Lab Hematol. 2016; 38(5):505-513.
15. Samama MM, Amiral J, Guinet C, Perzborn E, Depasse F. An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost. 2010;104(5):1078-1079.
16. Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015;40(3): 182-212.
17. Douketis JD, Woods K, Foster GA, Crowther MA. Bridging anticoagulation with low-molecular-weight heparin after interruption of warfarin therapy is associated with a residual anticoagulant effect prior to surgery. Thromb Haemost. 2005;94(3): 528-531.
18. O’Donnell MJ, Kearon C, Johnson J, et al. Brief communication: Preoperative anticoagulant activity after bridging low-molecularweight heparin for temporary interruption of warfarin. Ann Intern Med. 2007;146(3):184-187.
19. Douxfils J, Tamigniau A, Chatelain B, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost. 2013;110(4):723-731.
20. Rohde G. Determination of rivaroxaban—a novel, oral, direct Factor Xa inhibitor—in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;872(1-2):43-50.
21. Administration FaD. FDA Guidelines for Industry for Bioanalytical Method Validation. 2001.
22. Pernod G, Albaladejo P, Godier A, et al; Working Group on Perioperative Haemostasis. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP)—March 2013. Arch Cardiovasc Dis. 2013; 106(6-7):382-393.
23. Van Blerk M, Bailleul E, Chatelain B, et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost. 2015;113(1):154-164.
24. Cuker A. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis. 2015.
25. Godier A, Gouin-Thibault I, Rosencher N, Albaladejo P; Groupe d’Interet en Hemostase P. Management of direct oral anticoagulants for invasive procedures [In French]. J Mal Vasc. 2015;40(3): 173-181.
26. Douketis JD, Healey JS, Brueckmann M, et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015;113(3):625-632.
27. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126(13):1630-1639.
28. Steinberg BA, Peterson ED, Kim S, et al; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation. 2015;131(5): 488-494.
29. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation; BRIDGE Investigators. New Engl J Med. 2015;373(9): 823-833.
30. Douketis JD, Spyropoulos AC, Spencer FA, et al; American College of Chest Physicians. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(suppl 2): e326S-e350S.
31. Mar PL, Familtsev D, Ezekowitz MD, Lakkireddy D, Gopinathannair R. Periprocedural management of anticoagulation in patients taking novel oral anticoagulants: review of the literature and recommendations for specific populations and procedures. Int J Cardiol. 2016;202:578-585.
32. Adcock DM, Gosselin R. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thromb Res. 2015;136(1):7-12.
33. Gosselin RC, Francart SJ, Hawes EM, Moll S, Dager WE, Adcock DM. Heparin-Calibrated Chromogenic Anti-Xa Activity Measurements in Patients Receiving Rivaroxaban: Can This Test Be Used to Quantify Drug Level? Ann Pharmacother. 2015;49(7): 777-783.